Advertisement

Topics

Daiichi Sankyo Company Profile

02:17 EDT 17th October 2018 | BioPortfolio

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.


News Articles [129 Associated News Articles listed on BioPortfolio]

Daiichi Sankyo to restructure vaccines subsidiary

Daiichi Sankyo is set to restructure its wholly-owned Kitasato Daiichi Sankyo Vaccine subsidiary into a specialised manufacturing division to enhance...Read More... The post Daiichi Sankyo to restruct...

Glycotope GmbH: Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

TOKYO, BERLIN, BASKING RIDGE, NJ / ACCESSWIRE / July 30, 2018 / Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have entered into an exclusive ...

Deals this week: Daiichi Sankyo, MannKind, Dova Pharmaceuticals

Daiichi Sankyo has transferred 41 of its long-listed products to Alfresa Pharma. The transaction also includes products manufactured by Daiichi...Read More... The post Deals this week: Daiichi Sankyo,...

Daiichi Sankyo to develop new inflammatory disease drugs

Daiichi Sankyo has formed a new consortium focused on research and discovery of medicines over a period of five years...Read More... The post Daiichi Sankyo to develop new inflammatory disease drugs a...

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML

Tokyo, Munich and Basking Ridge, NJ – (August 1, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthr...

Daiichi Sankyo reports on results for leukemia candidate

Daiichi Sankyo's quizartinib, a drug being tested in a Phase III trial as a treatment for patients with relapsed or refractor -More- 

Daiichi Sankyo transfers 41 products to Alfresa Pharma

Daiichi Sankyo has announced plans to split and transfer its inventories to Alfresa Pharma, along with Japanese manufacturing and sales...Read More... The post Daiichi Sankyo transfers 41 products to ...

Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Significant Clinical Improvement Across Multiple Endpoints in Patients with Tenosynovial Giant Cell Tumor

Tokyo, Basking Ridge, NJ, and Munich – (June 4, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the phase 3 ENLIVEN study showed a statistically significan...

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Benicar [Daiichi Sankyo, Inc]

These highlights do not include all the information needed to use Benicar safely and effectively. See full prescribing information for Benicar. Benicar (olmesartan medoxomil) tablets Initial U.S. Appr...

Evoxac capsules(cevimeline hydrochloride) [Daiichi Sankyo Pharma Development]

EVOXAC Capsules(cevimeline hydrochloride)

Azor [Daiichi Sankyo, Inc.]

These highlights do not include all the information needed to use AZOR safely and effectively. See full prescribing information for AZOR. AZOR (amlodipine and olmesartan medoxomil) tablets, for oral u...

Welchol [Daiichi Sankyo, inc.]

These highlights do not include all the information needed to use Welchol safely and effectively. See full prescribing information for Welchol. Welchol (colesevelam hydrochloride) Tablet, Film Coated,...

Quixin [Vistakon Pharmaceuticals LLC]

QUIXIN (levofloxacin ophthalmic solution) 0.5%

PubMed Articles [19 Associated PubMed Articles listed on BioPortfolio]

Long-term outcomes of patients evacuated from hospitals near the Fukushima Daiichi nuclear power plant after the Great East Japan Earthquake.

After the accident of the Fukushima Daiichi nuclear power plant due to the Great East Japan Earthquake in March 2011, the Japanese government issued a mandatory evacuation order for people living with...

Atmospheric activity concentration of Sr and Cs after the Fukushima Daiichi Nuclear Accident.

On 11 March 2011, the Fukushima Daiichi Nuclear Power Plant (FDNPP) accident occurred and a large amount of radionuclides were discharged into the atmosphere. We have operated continuous aerosol sampl...

131I DOSE ESTIMATION FROM INTAKE OF TAP WATER IN THE EARLY PHASE AFTER FUKUSHIMA DAIICHI NUCLEAR POWER PLANT ACCIDENT.

In March 2011, the Fukushima Daiichi Nuclear Power Plant Accident occurred and a large amount of radionuclides was released. To study its effect, we estimated the internal exposure due to intake of ta...

Changes in the Soil to Brown Rice Concentration Ratio of Radiocaesium before and after the Fukushima Daiichi Nuclear Power Plant Accident in 2011.

Radiocaesium (Cs) mobility in soil is initially relatively high when the nuclide first comes into contact with soil, after which the mobile fraction decreases with time due to Cs fixation to soil part...

Twitter use in scientific communication revealed by visualization of information spreading by influencers within half a year after the Fukushima Daiichi nuclear power plant accident.

Scientific communication through social media, particularly Twitter has been gaining importance in recent years. As such, it is critical to understand how information is transmitted and dispersed thro...

Clinical Trials [12 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar® 40 mg Tablets of Daiichi Sankyo Inc., USA. Dosing periods of studies were ...

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

This study evaluates the non-inferiority of the new transdermal patch dosage form containing loxoprofen sodium (100 mg - Daiichi-Sankyo) in comparison with oral Loxonin® (60 mg tablet - D...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar 40 mg Tablets of Daichi Sankyo Inc. USA. Dosing periods of studies were sepa...

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Hong Kong proposed this non-interventional study (NIS)...

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Thailand proposed this non-interventional study (NIS) ...

Companies [28 Associated Companies listed on BioPortfolio]

DAIICHI SANKYO EUROPE GmbH and SHARE

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese e...

Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. ...

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that e...

ArQule, Inc. and Daiichi Sankyo Company, Limited

On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South ...

Daiichi-Sankyo

More Information about "Daiichi Sankyo" on BioPortfolio

We have published hundreds of Daiichi Sankyo news stories on BioPortfolio along with dozens of Daiichi Sankyo Clinical Trials and PubMed Articles about Daiichi Sankyo for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Daiichi Sankyo Companies in our database. You can also find out about relevant Daiichi Sankyo Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Adempas (riociguat)
The United States Food and Drug Administration (FDA) has approved on October 8th 2013 Adempas® (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record